{"id":227042,"date":"2025-12-13T06:03:26","date_gmt":"2025-12-13T12:03:26","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2025\/12\/a-review-of-the-clinical-progress-of-ct1812-a-novel-sigma-2-receptor-antagonist-for-the-treatment-of-alzheimers-disease"},"modified":"2025-12-13T06:03:26","modified_gmt":"2025-12-13T12:03:26","slug":"a-review-of-the-clinical-progress-of-ct1812-a-novel-sigma-2-receptor-antagonist-for-the-treatment-of-alzheimers-disease","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2025\/12\/a-review-of-the-clinical-progress-of-ct1812-a-novel-sigma-2-receptor-antagonist-for-the-treatment-of-alzheimers-disease","title":{"rendered":"A Review of the Clinical Progress of CT1812, a Novel Sigma-2 Receptor Antagonist for the Treatment of Alzheimer\u2019s Disease"},"content":{"rendered":"<p style=\"padding-right: 20px\"><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/a-review-of-the-clinical-progress-of-ct1812-a-novel-sigma-2-receptor-antagonist-for-the-treatment-of-alzheimers-disease2.jpg\"><\/a><\/p>\n<p>Alzheimer\u2019s disease (AD) is a neurodegenerative disease marked by the accumulation of toxic amyloid-beta (A\u03b2) oligomers. These oligomers are thought to cause synaptic dysfunction and contribute to neurodegeneration. CT1812 is a small-molecule sigma-2 receptor antagonist that is currently being investigated and tested as a potential disease-modifying treatment for AD. CT1812 acts by displacing A\u03b2 oligomers into the cerebrospinal fluid and preventing their interaction with receptors on neurons. Preclinical studies and early clinical trials of CT1812 show promising results and provide evidence for its potential to slow AD progression. This review outlines the role of A\u03b2 oligomers in AD, CT1812\u2019s mechanism of action, and the effectiveness and limitations of CT1812 based on preclinical and clinical studies.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Alzheimer\u2019s disease (AD) is a neurodegenerative disease marked by the accumulation of toxic amyloid-beta (A\u03b2) oligomers. These oligomers are thought to cause synaptic dysfunction and contribute to neurodegeneration. CT1812 is a small-molecule sigma-2 receptor antagonist that is currently being investigated and tested as a potential disease-modifying treatment for AD. CT1812 acts by displacing A\u03b2 oligomers [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,47],"tags":[],"class_list":["post-227042","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-neuroscience"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/227042","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=227042"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/227042\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=227042"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=227042"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=227042"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}